Kornimate/medical-research-clean huggingface dataset:
evaluation of endorings-2-assisted colonoscopy: a new accessory for improvement of adenoma detection rate?

Conditions: Colonic Adenoma; Colonic Polyp; Colonic Neoplasms; Colonoscopy

Summary: screening colonoscopy for colorectal cancer is essential to diagnose and remove adenomas, precancerous stages of colorectal cancer. unfortunately approximately 25 % of all adenomas are missed during the examination. recently a new colonoscopy accessory, the endorings-2 (endoaid ltd., casearea, israel), has been designed to improved the detection of adenomas during colonoscopy (adenoma detection rate). endorings-2 is a silicone-rubber device that is fitted on the colonoscope and is equipped with circular flexible silicon rings mechanically stretching the colonic folds during withdrawal. this study aims to evaluate the efficacy of endorings-2 to improve the adenoma detection rate in a prospective, blinded clinical trial. 292 patients with an indication for a screening colonoscopy shall be included (1:1 randomization in standard colonoscopy versus endorings-2-assisted colonoscopy).


Eligibility criteria:
inclusion criteria: * patients with an indication for a screening colonoscopy. exclusion criteria: * patients under 18 years, pregnancy * patients with prior colectomy or partial colectomy * patients with a history of colorectal cancer * patients with hereditary polyposis syndromes (fap, hnpcc) * patients with a stricture of the colon * patients receiving anticoagulation prohibiting a colonoscopy * inability to have a patient education * bad conditions prohibiting a colonoscopy

Keywords: colonoscopy; adenoma detection rate; endorings-2; endorings; device-assisted colonoscopy
a single-arm study to evaluate safety and effectiveness of vx-548 for acute pain

Conditions: Pain

Summary: the purpose of this study is to evaluate the safety and effectiveness of vx-548 in treating acute pain.


Eligibility criteria:
key inclusion criteria: * body mass index (bmi) of greater than or equal to (≥) 18.0 to less than (\<) 40.0 kilogram per meter square (kg/m\^2) * non-surgical participants with pain of new origin (not related to a prior known condition) that is moderate or severe on the verbal categorical rating scale (vrs) and ≥4 on the numeric pain rating scale (nprs) * surgical participants reporting pain at the surgical site that is moderate or severe on the vrs and ≥4 on the nprs key exclusion criteria: * surgical participants: * history of previous surgery due to the same condition, except for procedures for which a previous surgery on the contra-lateral limb or organ is allowed * history of a prior surgical procedure in the same region of the body that resulted in any perioperative complications or that, in the opinion of the investigator or medical monitor, would preclude participation in the study * history of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant other protocol defined inclusion/exclusion criteria may apply.
pharmacokinetics, safety, and tolerability of csl760, an intravenous anti-sars-cov-2 hyperimmune globulin, in healthy adult subjects

Conditions: Coronavirus Disease 2019 (COVID-19)

Summary: csl760 is a human hyperimmune product of the purified gamma immunoglobulin (igg) fraction of human plasma containing polyvalent neutralizing antibodies to sars-cov-2 (severe acute respiratory syndrome coronavirus 2). csl is evaluating csl760 as a passive immunotherapy for covid-19 (coronavirus disease 2019).


Eligibility criteria:
inclusion criteria: * male or female 18 to 65 years of age * female subjects must be postmenopausal or have a negative pregnancy test * body weight in the range of ≥ 50 kg and ≤ 100 kg and have a body mass index of ≥ 18 to ≤ 32 kg/m2 exclusion criteria: * history of acute or chronic renal failure, thromboembolism, chronic respiratory illness, aseptic meningitis syndrome, or recurrent severe headaches or migraines. * positive viral serology test for hiv -1/2 antibody, hepatitis b virus surface antigen, or hepatitis c virus antibody * positive viral serology test for sars-cov-2 antibodies * received any live viral or bacterial vaccinations within 8 weeks * evidence of current active infection. * known malignancy or a history of malignancy in the past 5 years * female subject of childbearing potential or fertile male subject either not using or not willing to use an acceptable double barrier method of contraception to avoid pregnancy during the study
effectiveness of adherence therapy for schizophrenia

Conditions: Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder

Summary: when compared with those in the control (usual care) group, participants in the at group are expected to demonstrate significant improvements immediately and at three, six and 12 months after completion of the intervention in: level of medication adherence, readmission rate, mental status, insight into treatment, and level of functioning.

when compared with those in the control (usual care) group, participants in the at group are expected to demonstrate significant improvements immediately and at three, six and 12 months after completion of the intervention in the following aspects: 1. level of adherence to antipsychotic medication, 2. rate and length of psychiatric hospital readmission, 3. mental status, 4. insight and attitude into illness and treatment, and 5. level of functioning. the primary outcomes are level of antipsychotic medication adherence, re-hospitalization rates and mental status; and the patients' drug attitude will be the mediating factor of the at.

Eligibility criteria:
inclusion criteria of the patients include those who: * are hong kong chinese residents; * have a primary diagnosis of schizophrenia or its subtypes such as schizophreniform and schizoaffective disorders not more than 3 years; * have been prescribed oral antipsychotics for at least 1 month; * are aged 18-65 years; * have positive and negative syndrome scale (panss) score \>60 and are judged by the case community psychiatric nurse/psychiatrist as non-adherents; and * are able to understand cantonese/mandarin. patients will be excluded if they have: * only depot/intramuscular injections as regular psychiatric medication; * co-morbidity of learning disability and organic brain disease, or clinically significant medical diseases; * participated in adherence therapy; and/or * visual, language or communication difficulty.

Keywords: schizophrenia adherence therapy medication randomized controlled trial cost-effectiveness
risks of bacterial and fungal superinfection in patients with covid-19

Conditions: COVID-19

Summary: infection with bacteria or fungi can be deadly. often, these types of infections can lead to an increase in the severity of illness requiring intensive care unit (icu) admission, prolonged duration of treatment and further risks associated with additional infections and superinfections. these are also called hospital acquired secondary infections. patients who contract covid-19 and require an icu admission are at increased risk of contracting these secondary infections, and receive certain medications that can lower your body's immune response. in covid-19 patients who require these treatments, it is unclear what affect these medications can have on developing an additional infection as well as the rate of recovery/survival. this study is evaluating the effect these medications have on the development of secondary infections and rate of survival of covid-19 patients that have been admitted to icus.


Eligibility criteria:
inclusion criteria: * hospital admission date from 1 july 2020 to 30 june 2021 * positive test for covid-19 collected within 1 week of admission date * icu admission within 60 days after hospital admission date exclusion criteria: * hospital admission shorter than 5 days * persons younger than 18 years of age

Keywords: secondary infections bacterial infections fungal infections
application of point-of-care ultrasound in rapid assessment of cardiac arrest patients

Conditions: Cardiac Arrest; Point-of-care Ultrasound; Cardiopulmonary Resuscitation

Summary: to quickly assess the patient's cardiac function and structure through ultrasound

monitor the peripheral arterial pulse and flow velocity, monitor the patient's lung and diaphragm muscle movement, monitor the patient's optic nerve sheath and cerebral blood flow, observe the morphology and blood flow of the liver and kidney and other parenchymal organs, comprehensive evaluation of patient resuscitation quality. for patients with cardiac arrest undergoing cardio pulmonary resuscitation (cpr), the above monitoring was completed by ultrasound, and compared with the parameters obtained by end-expiratory carbon dioxide (etco2) and compression feedback device, to evaluate the feasibility of ultrasound to evaluate the quality of cpr. after the reliability evaluation was completed, parameters were further used to guide cpr quality improvement through ultrasound, end-expiratory carbon dioxide (etco2), and compression feedback device.

Eligibility criteria:
inclusion criteria: * voluntarily participate and sign a written informed consent; * male or female above 18; * patients who are sent to the emergency room of our hospital with symptoms of "cardiopulmonary resuscitation"; exclusion criteria: * there is trauma in the ultrasound examination site and it is not suitable for ultrasound examination; * entering the emergency room without vital signs for more than 30 minutes; * the appearance of corpse corpses; * there is life-threatening and irreversible damage; * other investigators consider it inappropriate and the patient or family member refuses;

Keywords: cardiac arrest point-of-care ultrasound cardiopulmonary resuscitation quality
a study of mevidalen (ly3154207) in participants with alzheimer's disease

Conditions: Alzheimer Disease

Summary: the main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate alzheimer disease (ad) dementia. this is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, ad symptoms, physical activity, irritability or anxiety. the study is expected to last approximately 26 weeks and may include up to 14 visits.


Eligibility criteria:
inclusion criteria: * have gradual and progressive decline in memory function for greater than or equal to 6 months that is severe enough to interfere with activities of daily living. * have mmse score of 13 to 24. * have eligibile plasma p-tau or historical evidence of ad pathology. * have a reliable study partner who will provide written informed consent to participate, is in frequent contact with the participant and will be available at designated times. * males with partners of childbearing potential must agree to abide with provided contraception guidance. exclusion criteria: * are individuals of childbearing potential. * have significant central nervous system or psychiatric disease, other than ad, that in the investigator's opinion may affect cognition or the ability to complete the study (e.g: head trauma, stroke, seizure disorder etc.,). * have cardiovascular-related risk factors or history that include uncontrolled hypertension, heart failure, stroke; or liver-related abnormalities. * use of moderate or strong cyp3a4 inhibitors or inducers. * have participated within the last 30 days in a clinical trial involving an investigational product. * participant is, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.
nicotinamide riboside in sars-cov-2 (covid-19) patients for renal protection

Conditions: SARS-CoV-2 Infection; Acute Kidney Injury

Summary: an interventional clinical trial using oral nicotinamide riboside (nr) in hospitalized patients with covid-19 infection and acute kidney injury to determine the effect of nr on whole blood nicotinamide adenine dinucleotide (nad+) levels and to evaluate safety of the use of nr.

the study team chose a treatment protocol with nr as a treatment for patients who will be admitted with covid-19 related illness and develop aki after admission. treatment duration will be for 10 days and the primary study endpoint will be the change in whole blood nad+ from baseline to end of treatment in nr group vs placebo group. the study team will evaluate whole blood nad+ levels as a marker of efficacy and biological effect of nr.

Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form from a participant or legally authorized representative (lar); 2. male or female, \>18 years old; 3. hospitalized participants with a laboratory diagnosis of covid-19 infection 4. evidence of persistent aki as defined by the kidney disease: improving global outcomes (kdigo) guidelines (table 3); 5. willing to adhere to the study intervention regimen; exclusion criteria: 1. hypersensitivity to nicotinamide riboside (nr); 2. pregnant or lactating women confirmed with positive laboratory pregnancy tests as per local requirements; 3. egfr \<15 ml/min/1.73 m2 as per the chronic kidney disease epidemiology collaboration equation at admission lab; 4. maintenance renal replacement therapy or initiation of renal replacement therapy before randomization 5. currently on nr or nicotinamide or vitamin b3 (niacin) supplementation (multivitamins are allowed); 6. concomitant cirrhosis of liver or acute liver failure; 7. any medical history or condition that might, in the opinion of the attending physician, put the participant at significant risk if he/she were to participate in the trial; 8. individuals with kidney transplant; 9. individuals with blood platelet count \<100,000/microl
what women want: real time results during screening mammography in the era of patient-experience driven care

Conditions: Breast Carcinoma

Summary: this study explores why patients may want to receive real-time imaging results during a screening mammogram appointment at an md anderson breast imaging center. real-time imaging results means women receive the results of the mammogram right away during the same clinic visit. information from this study may help researchers better understand patient preferences to enhance patient-experience driven care.

primary objective: i. to identify factors that may influence a patient's desire to receive real-time imaging results during their screening mammogram appointment at a breast center. outline: participants complete an online questionnaire over 5 minutes regarding information on patient demographics and preferences for receiving real-time appointment imaging results.

Eligibility criteria:
inclusion criteria: * all female patients scheduled for a screening mammogram at one of our three md anderson cancer center (mdacc) breast imaging houston area location centers * patient \>= 30 years of age * able to complete an electronic informed consent for the study exclusion criteria: * patients not scheduled for a screening mammogram at one of the three imaging facilities
autonomic regulation in prader-willi syndrome

Conditions: Autonomic Dysfunction

Summary: to evaluate autonomic regulation in patients with prader-willi syndrome with sleep-disordered breathing.

to evaluate the relationship between narcolepsy and sleep-disordered breathing, the natural course of untreated or treated sleep-disordered breathing and its impacts on autonomic regulation in patients with prader-willi syndrome with sleep-disordered breathing.

Eligibility criteria:
inclusion criteria: * 7-75 y/o prader-willi syndrome patients or healthy subjects * can perform polysomnography, multiple sleep latency test * orthostatic methods for autonomic function test * can perform pulmonary function test. exclusion criteria: * less than y/o, or larger then 75 y/o * cannot perform polysomnography, multiple sleep latency test * cannot orthostatic methods for autonomic function test * cannot perform pulmonary function test * use of sedatives or drugs affecting autonomic function
pain perception in alzheimer's disease

Conditions: Dementia Alzheimer Type

Summary: the purpose of this study is to determine response to pain in alzheimer's disease.we plan to study the effect of diffuse noxious inhibitory controls(counterirritation phenomenon)and the autonomic nervous system reaction(reflected by the heart rate) in alzheimer's disease. the study's hypothesis is that pain perception and autonomic nervous system reaction are altered in alzheimer's disease.


Eligibility criteria:
inclusion criteria: - clinical diagnosis of alzheimer's disease must be able to understand a simple pain scale exclusion criteria: neuropathy psychotropic drugs use -
sodium nitroprusside for blood pressure reduction in the icu (snp2)

Conditions: Hypertension

Summary: nitroprusside is used commonly in the intensive care unit for long periods of time in order to reduce blood pressure. it is not known if the body compensates over time to the blood pressure lowering, and if when the nitroprusside is stopped the blood pressure goes up at a faster rate and is higher than it was at the start of the treatment. this study will answer these questions.

this is a phase 2, multicenter, randomized, double-blind placebo-controlled, parallel group study to determine the persistence of the effect of snp on blood pressure and to assess the potential for rebound hypertension associated with prolonged infusion in pediatric subjects. the primary endpoint is the change in map during the blinded study drug administration phase in the absence of other stimuli.

Eligibility criteria:
inclusion criteria: 1. subject is less than 17 years of age. 2. an in-dwelling arterial line is clinically indicated. 3. subject's parent or legal guardian is willing and able to give informed parental permission signing and dating an irb-approved informed parental permission containing all of the elements of informed consent, and subject provides assent, signing an irb-approved and -required informed assent, if applicable. 4. subject is anticipated to require a minimum of 20 mm hg (15 mm hg for subjects \< 2 years old) reduction in map for at least 12 hours using snp \[i.e., mapb1 - mapb2 ≥ 20 mm hg (15 mm hg for subjects \< 2 years old)\] exclusion criteria: 1. subject weighs \< 3.0 kg. 2. subject has a known allergy to snp. 3. subject has a known mitochondrial cytopathy with a disorder of oxidative phosphorylation or of respiratory chain enzymes. 4. subject has a contraindication to vasodilator therapy for control of blood pressure during surgery or in the intensive care unit. 5. subject has raised intracranial pressure. 6. subject is anticipated to need anti-hypertensive drugs other than sodium nitroprusside either iv (e.g. dexmedetomidine, esmolol, etc.) or epidural (e.g.local anesthetics, clonidine, etc.) within three terminal half-lives (3x t½ β) of the blinded study drug period. however, patients receiving stable doses of an anti-hypertensive drug(s) prior to the initiation of study drug may be enrolled. 7. subject has any serious medical condition which, in the opinion of the investigator, is likely to interfere with study procedures. 8. subject is moribund (death likely to occur within 48 hours). 9. subject has a positive result for the urine or serum hcg test administered at screening. 10. subject has participated in other clinical trials for investigational drugs within 30 days prior to enrollment 11. subject has received or will have received sodium thiosulfate within 6 hours prior to the start of the open-label period. 12. subject is either on, or anticipated to be on, ecmo.

Keywords: nitroprusside intensive care unit hypertension blood pressure reduction
implant supported single crowns with different retention modes

Conditions: Complications: Inflammatory Reactions, Mechanical Complications

Summary: this study aims to examine the inflammatory response mediated by mmp-8 (matrix metalloproteinase-8 ) level in peri-implant sulcus fluid adjacent to screw-retained, cemented or using the acuris-system fixed single implant crowns as well as changing of the marginal bone level within the first year after implant restoration. furthermore periodontal parameters, patient satisfaction and possible occurring biological or technical complications will be evaluated.

after giving their written consent volunteers will be screened and eligible subjects will be randomized to three different groups. in group 1 acuris® is used as fixation type; in group 2 screw retention, and in group 3 cementation is used. after 3 months of submerged healing the dental implants will be restored with all ceramic single implant crowns, fixed by using the randomized fixation mode. follow-up visits till one year after implant restoration will be performed. at least 11 study visits during 16 months will be conducted.

Eligibility criteria:
inclusion criteria: * capability of giving an informed consent * good health as defined by the subjects medical history (no contraindications as described in the exclusion criteria below) * age 18 to 99 years * good periodontal status: bop \ 4mm * no heavy smokers (\< 10 cigarettes/day) * at least 1 missing tooth in the premolar and molar region (with at least a mesial neighboring tooth/implant showing adequate hard- and soft tissue situation without the need of crestal hard- or soft tissue augmentation) either in the maxilla or in the mandible requiring implant therapy for reconstruction, requiring sinus floor augmentation or not. exclusion criteria * insufficient bone volume for implant placement requiring gbr (guided bone regeneration) procedure in crestal area. * heavy smokers (\>10 cigarettes/day) * medication with a contraindication for implant therapy (especially antiresorptive therapy, ongoing or recently completed local radiotherapy, systematic diseases, ongoing immunosuppressive therapy, functional disorders like bruxism). * skeletal immaturity. * any active malignancy or ongoing treatment for malignancy. * an active infection (e.g. caries, gingivitis, periodontitis) at or in the neighboring area of the operative site. * pregnancy * unable or unwilling to return for follow-up visits for a period of at least 16 months

Keywords: mmp-8 marginal bone level conometric concept - acuris crown retention all-ceramic crown
lidocaine infusion in hystroscopy

Conditions: Pain

Summary: lidocaine infusion in hystroscopic media versus oral diclofenac


Eligibility criteria:
inclusion criteria: * age 18-35 years * bmi 18.5-30 kg/m2 * diagnostic hystroscope exclusion criteria: * previous cervical surgery * cervical stenosis * pid * allergy to nsaid * gastritis or peptic ulcer